Benzinga's Top Pre-Market NASDAQ Gainers (SVNT, CYPB, UTSI, NOVL)

Loading...
Loading...
Savient Pharmaceuticals Inc
SVNT
rose 27.37% to $18.80 in the pre-market session. FDA has approved SVNT's gout drug for adults who were not getting any results from the conventional therapy. Cypress Bioscience Inc
CYPB
added 13.39% to $3.98 in the pre-market session. Ramius Value and Opportunity Advisors LLC initiated an offer to buy all the outstanding shares of CYPB at $4.25 per share. UTStarcom Inc
UTSI
moved up 7.25% to $2.07 in the pre-market session. UTSI has won the bid for the Equipment Purchase Project of Jinan Radio & TV Network Center, thereby becoming the exclusive broadband solution provider of the Center. Novell Inc
NOVL
soared 5.03% to $5.85 in the pre-market trading. NOVL's trailing-twelve-month gross margin is 78.54%. Read more
from Benzinga's Company news.Click here to get trading ideas that could bring you a 100% return.
Posted In: NewsPre-Market OutlookIntraday UpdateMarketsTrading IdeasTop Pre-Market NASDAQ Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...